

PRESS NEWS

Gradientech announces first external QuickMIC® system installation

Uppsala, March 1, 2021. Gradientech AB (publ) today announced that their QuickMIC system for rapid antibiotic susceptibility testing (AST) is currently being used for a beta test study by Uppsala University Hospital, Sweden.

The installed system consists of QuickMIC instrument modules, which received approval for research use during last year. The study comprises the analysis of 30 clinical samples from sepsis patients with gram-negative bacteria.

"We are very excited about the ongoing collaboration with Uppsala University Hospital and we foresee a long-term collaboration that adds value to both parties. Placing our QuickMIC system externally for the first time was an important milestone for Gradientech. The input received so far from the clinical microbiology staff involved in beta testing has been very positive", said Sara Thorslund, CEO of Gradientech.

"We have been collaborating with Gradientech since the inception of their ultra-rapid AST system. It is a pleasure for us to have the opportunity to test QuickMIC in our laboratory and to experience the benefits the system has to offer", commented Ehsan Ghaderi, Head of Bacteriology at Uppsala University Hospital.

Uppsala University Hospital is one of Sweden's largest hospitals and it is a source of both unique medical knowledge and the most advanced care available. The hospital is a key partner for Gradientech that will continue to have an important role in future studies aimed towards the regulatory CE-IVD approval of the QuickMIC system.

For further information, please contact:

Sara Thorslund, PhD, CEO Gradientech

Tel: +46 736 29 35 80, email: sara.thorslund@gradientech.se

Gradientech is a diagnostics company developing the in vitro diagnostic QuickMIC® system, a new platform for ultra-rapid antibiotic susceptibility testing based on phenotypic bacterial growth analysis. The system is expected to become the most rapid solution for determining appropriate antibiotic treatment of sepsis patients. Rapid antibiotic susceptibility testing is vital for increasing sepsis patient survival, reducing healthcare costs and lowering the spread of antibiotic resistance.

www.gradientech.se